Serious kidney science. Proven results.
The region's premier site for kidney studies. Trials in Augusta, Georgia for more than 25 years, run by the same board-certified nephrologists who care for the CSRA every day. Study care is provided at no cost, and your insurance is never billed.
Refer a patient. Keep the loop closed.
Send us a patient for a research evaluation and you stay informed at every step. We confirm eligibility, manage all study-related care, and report back to you directly.
A proven kidney site, feasibility to closeout.
Phase 1b, Phase 2a, Phase 2b, and Phase 3 trials inside the largest private-practice nephrology group in the CSRA: board-certified investigators, GCP-trained and ACRP-certified coordinators, a dedicated regulatory specialist, on-site pharmacy and lab, and your central IRB accepted.
We practice medicine, and help write it.
For more than 25 years the nephrologists of Nephrology Associates, PC have served as principal and site investigators on the trials that define modern kidney care: SPRINT, DAPA-CKD, the vadadustat anemia program. They brought those therapies to the people of the CSRA first. Southeastern Clinical Research Institute is where that work happens: the region's premier site for kidney studies, run to the standard sponsors expect of a national center of excellence.
- Investigators published in the New England Journal of Medicine
- The largest private-practice nephrology population in the CSRA, across seven offices
- Trusted by Eli Lilly, AstraZeneca, Bayer, Novo Nordisk, Novartis, GSK, Merck, and Amgen
- A dedicated research facility in Augusta's medical district: on-site pharmacy and lab, private monitor space
- Phase 1b, Phase 2a, Phase 2b, and Phase 3 trials, 200+ studies and counting
The research institute, in motion
1521 Anthony Road in Augusta's medical district: a dedicated research site, its laboratory, and the team that runs every study.
Studies open today
Two studies are open to enrollment today, with more in follow-up. Eligibility is confirmed by our study team.
CKD & High Blood Pressure
Baxdrostat in combination with dapagliflozin, evaluated for renal outcomes and cardiovascular mortality in chronic kidney disease (BaxDuo-Pacific).
Who it is forAdults with chronic kidney disease and high blood pressure.
IgA Nephropathy
Extended TARPEYO® (delayed-release budesonide) treatment in adults with primary IgA nephropathy (NefXtend).
Who it is forAdults with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg.
Elevated Lipoprotein(a)
Lepodisiran for cardiovascular risk reduction in adults with high lipoprotein(a) (ACCLAIM-Lp(a)). Enrollment closed; participants are followed through 2029.
Obesity · Heart & Kidney
Retatrutide's effect on cardiovascular and kidney outcomes in adults living with obesity (TRIUMPH-Outcomes). Enrollment closed; participants are followed through 2029.
Led by Dr. Matthew Diamond, DO, FASN, FACP
Every SCRI investigator is a practicing, board-certified nephrologist at Nephrology Associates, PC: the same physicians our patients see in clinic, and the authors behind the evidence.
Dr. Matthew DiamondDO, FASN, FACP
Former Professor of Medicine at the Medical College of Georgia and a SPRINT site investigator, published in the New England Journal of Medicine on intensive blood-pressure control and chronic kidney disease. A Fellow of both the American Society of Nephrology and the American College of Physicians, he directs every study SCRI runs.
“Research here is not separate from care. It is an extension of it.”
Barton BrezinaMD
H. Doug HubertMD
Devesh PatelMD
S. Nabil BabarMD
Ryan AltenburgDO
James StenardMD, MS
Michael B. WhitlowMD
Nadeem AfzalMD
Trevor TobinDO
Therapeutic areas
Our investigators concentrate on the conditions that drive the greatest burden of kidney disease across the Southeast.
Chronic Kidney Disease
Disease-modifying therapies aimed at slowing progression and protecting function across CKD stages.
Diabetic Kidney Disease
Agents that protect the diabetic kidney, including SGLT2 and non-steroidal MRA pathways.
Cardiorenal Protection
Studies at the intersection of heart and kidney disease, including elevated lipoprotein(a) and obesity outcomes.
Glomerular Disease
Investigational therapy for IgA nephropathy, lupus nephritis, and other immune-mediated kidney disease.
Anemia & Mineral Bone
Novel approaches to the anemia and mineral-bone complications of advanced kidney disease.
Hypertension
Trials targeting resistant and uncontrolled blood pressure, a principal driver of kidney decline.
Dialysis
Drug and device studies in hemodialysis and peritoneal dialysis: home hemodialysis, infection detection, anticoagulation.
Additional experience across dialysis access, hyperparathyroidism, hyperphosphatemia, iron deficiency, hyperlipidemia, proteinuria, and immunology.
Trusted by the sponsors writing the next chapter.
Sponsor partners over more than 25 years: global pharma, emerging biotech, and device companies.
What sponsors say
SCRI is the site you hope for on a nephrology program: investigators who see these patients every day, coordinators who know the protocol cold, and enrollment that arrives clean.
Eli Lilly and CompanyClinical Trial Manager
Ready to get started?
See if a study fits
Tell us a little about your kidney health and we will call you back. It costs nothing to ask.
Start here →Refer a patient
We screen against every open protocol and report the outcome back to your office, either way.
Refer now →Bring us your protocol
Call to discuss feasibility with a site that has delivered kidney trials for more than 25 years.
Call (706) 922-3005 →Southeastern Clinical Research Institute, LLC · 1521 Anthony Road, Augusta, Georgia 30904 · (706) 922-3005 · Fax (706) 722-5843
Two things worth reading
Written by the research team at the region's kidney research center, for patients, physicians, and sponsors alike.
Why a research institute owned by the treating nephrologists finds the patient, keeps the patient, and returns clean data. With the record to show for it.
Read the paper → From the blog Polycystic kidney disease: the research behind the first treatment, and Augusta's part in itWhat ADPKD is, what tolvaptan does, what comes next, and what families can do now.
Read the article →